Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01329913 | Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) | PHASE1 | COMPLETED | 36 | — | — | May 1, 2011 | Apr 1, 2012 | Feb 5, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| GT1-HCV 200 mg | EXPERIMENTAL | - |
| GT1-HCV 400 mg | EXPERIMENTAL | - |
| GTI-HCV 800 mg | EXPERIMENTAL | - |
| GT3-HCV 200 mg | EXPERIMENTAL | - |
| GT3-HCV 400 mg | EXPERIMENTAL | - |
| GT3-HCV 800 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK-6325 | DRUG | Two 100 mg capsules, orally, once per day for 7 days |
| Placebo to MK-6325 | DRUG | Two 100 mg capsules, orally, once per day for 7 days |
Inclusion criteria: * Body mass index (BMI) of 18 to ≤37 kg/m\^2. * Stable health * No clinically significant abnormality on electrocardiogram (ECG) * Clinical diagnosis of chronic HCV infection (G1 or G3) for at least 6 months and detectable HCV RNA in peripheral blood. Exclusion criteria: * Pre...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |